GuidelineThe Journal of laryngology and otology2016
Investigation and management of the unknown primary with metastatic neck disease: United Kingdom National Multidisciplinary Guidelines.
Guideline in The Journal of laryngology and otology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06578871 (Surgery for the Unknown Primary in the Era of p16-positive Oropharyngeal Squamous Cell Carcinoma), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Surgery for the Unknown Primary in the Era of p16-positive Oropharyngeal Squamous Cell Carcinoma: Reducing Ionizing Radiation (SUPERIOR): A Randomized Trial
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.
- Differentiation of lymphomatous, metastatic, and non-malignant lymphadenopathy in the neck with quantitative diffusion-weighted imaging: systematic review and meta-analysis.Neuroradiology · 2019Pooled it
- Intraoperative Indocyanine Green Fluorescence Enables Primary Tumor Localization and Treatment De-Escalation in SCCUP: A Case Report.Head & neck · 2026Article
- Carcinoma of unknown primary (CUP) of the head and neck: state of the art and future perspectives.Frontiers in oncology · 2026Review
- Mucoepidermoid carcinoma of unknown primary in the head and neck: a case report and review of the literature.The Journal of laryngology and otology · 2025Review
- Evaluation of Efficacy of Neoadjuvant Immunochemotherapy for Cervical Metastatic Squamous Cell Carcinoma of Unknown Primary.Cancer medicine · 2025Article
- Patterns of Failure in Head and Neck Carcinoma of Unknown Primary: Insights from a Tobacco-Associated Cancer Cohort.South Asian journal of cancer · 2025Article
- The Use of Fluorescent Markers to Detect and Delineate Head and Neck Cancer: A Scoping Review.Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2025Article
- Cervical Lymph Node Metastasis of Unknown Origin and Remote Primary at a Tertiary Cancer Centre in North India: Case Series with Review of Literature.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- Head and Neck Squamous Cell Carcinoma of Unknown Primary: A Diagnostic Work-Up.The oncologist · 2024Article
- Clinical practice guidelines for management of head and neck squamous cell carcinoma of unknown primary: an AGREE II appraisal.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023Review
- High Frequency Jet Ventilation or Mechanical Ventilation for Panendoscopy for Cervicofacial Cancer: A Retrospective Study.Journal of clinical medicine · 2023Article
- [Cancer of unknown primary (CUP)-single-site, oligometastatic, and in the head and neck region].Radiologie (Heidelberg, Germany) · 2023Review
- A Systematic Review of Diagnostic and Prognostic Biomarkers for Head and Neck Cancer of Unknown Primary: An Unmet Clinical Need.Diagnostics (Basel, Switzerland) · 2023Review
- Review
- Intraoperative delineation of p16+ oropharyngeal carcinoma of unknown primary origin with fluorescence lifetime imaging: Preliminary report.Head & neck · 2022Article
- Methodology for the development of National Multidisciplinary Management Recommendations using a multi-stage meta-consensus initiative.BMC medical research methodology · 2022Article
- Oncologic Panendoscopy: Description of an Optimized Procedure Based on Our Experience.International archives of otorhinolaryngology · 2022Article
- Review
- Impact of Neck Dissection in Head and Neck Squamous Cell Carcinomas of Unknown Primary.Cancers · 2021Article
- Treatment Outcomes of Patients with Head and Neck Squamous Cell Carcinoma of Unknown Primary.Chonnam medical journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. It discusses the evidence base pertaining to the management of metastatic neck disease in the setting of an unknown primary and provides recommendations on the work up and management for this group of patients receiving cancer care. Recommendations • All patients presenting with confirmed cervical lymph node metastatic squamous cell carcinoma and no apparent primary site should undergo: ○ Positron emission tomography-computed tomography whole-body scan. (R) ○ Panendoscopy and directed biopsies. (R) ○ Bilateral tonsillectomy. (R) • Tongue base mucosectomy can be offered if facilities and expertise exists. (G) • Concomitant chemotherapy with radiation should be considered in patients with an unknown primary. (R) • Concomitant chemotherapy with radiation should be offered to suitable patients in the post-operative setting, where indicated. (R) • Neo-adjuvant chemotherapy can be used in gross 'unresectable' disease. (R) • Patients should be followed up at least two months in the first two years and three to six months in the subsequent years. (G) • Patients should be followed up to a minimum of five years with a prolonged follow up for selected patients. (G) • Positron emission tomography-computed tomography scan at three to four months after treatment is a useful follow-up strategy for patients treated by chemoradiation therapy. (R).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.